Japan Target Of Acquisitions, New Generics By Swiss-Based Sandoz
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers are being targeted for acquisition by Sandoz, the generics subsidiary of Switzerland-based Novartis